Global Infrastructure Partners, a part of BlackRock, has pledged Rs 2,000 crore, and the investment offers a greenshoe option ...

Cipla has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus.

BlackRock is injecting Rs 3,000 crore into Aditya Birla Group's renewable energy arm, Grasim, valuing the business at Rs ...

The Humanoids Summit is expanding to Asia with its first Japanese edition in Tokyo, scheduled for May 28?29, 2026 at the Takanawa Convention Center. The site of this event reflects Japan's rising ...

Green Impact Partners Inc. (TSXV: GIP) ("GIP" or the "Company") announces the cancelation of the previously announced LIFE ...

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...

The acquisition promises $200M in customer and community benefits, a rate freeze, and local leadership continuity.

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial.

About Green Impact Partners Inc. Green Impact Partners, Inc. is a clean energy company. The firm is focused on developing renewable natural gas projects throughout North America. It operates in the ...

Researchers adjusted for confounders like age, hypertension, cardiovascular disease, and other comorbidities. The refined results indicated GLP-1 users had a 16% lower risk of developing epilepsy ...